House of Commons' Standing Committee on Health: Development of a National Pharmacare Program
Document Type
Working Paper
Publication Date
5-2-2016
Abstract
Canada should implement national pharmacare consistent with the principles outlined in the Pharmacare 2020 report Morgan et al 2015a The best evidence we have shows that national pharmacare will save approximately 7 billion and more importantly hundreds of lives each year Morgan et al 2015bThe issue then is not whether to institute national pharmacare but how For even though the need for national pharmacare has been plain since the 1964 Hall Commission the landscape of medicine and pharmaceuticals has changed dramatically since then Of particular note is the pharmaceutical industry's growing interest in drugs that target relatively small patient populations often described interchangeably as 'orphan' 'niche' or 'specialty' drugs in the pursuit of socalled 'personalized' or 'precision medicine' This brief focuses specifically on the challenges posed by the push for more personalized medicine These challenges serve to underscore why national pharmacare is needed and define some of its essential features
Recommended Citation
Matthew Herder, “House of Commons' Standing Committee on Health: Development of a National Pharmacare Program” (2016) Dalhousie University Schulich School of Law Working Paper No 20.
Comments
Research Papers, Working Papers, Conference Papers.